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Abstract
Aims: Myelin oligodendrocyte glycoprotein antibodies (MOG-IgG) have been pro-
posed to define “MOG encephalomyelitis” (MOG-EM), with published diagnostic and 
“red flag” criteria. We aimed to evaluate these criteria in a routine clinical setting.
Methods: We retrospectively analyzed patients with borderline/positive MOG-IgG 
and applied the diagnostic and red flag criteria to determine likelihood of MOG-EM 
diagnosis. Para-/clinical parameters were described and analyzed with chi-square 
test.
Results: In total, 37 patients fulfilled MOG-EM diagnostic criteria (female-to-male 
ratio: 1.6:1, median onset age: 28.0 years [IQR 18.5-40.5], n = 8 with pediatric onset). 
In 24/37, red flags were present, predominantly MOG-IgG at assay cutoff and/or MRI 
lesions suggestive of multiple sclerosis (MS). As proposed in the consensus criteria, 
these patients should rather be described as “possible” MOG-EM. Of these, we clas-
sified 13 patients as “unlikely” MOG-EM in the presence of the red flag “borderline 
MOG-IgG” with negative MOG-IgG retest or coincidence of ≥1 additional red flag. 
This group mainly consisted of patients diagnosed with MS (n = 11). Frequency of 
cerebrospinal fluid (CSF-)—specific oligoclonal bands (OCB) is significantly lower in 
definite vs possible and unlikely MOG-EM (P = .0005).
Conclusion: Evaluation of diagnostic and red flag criteria, MOG-IgG retesting (incl. 
change of assay), and CSF-specific OCB are relevant in clinical routine cohorts to dif-
ferentiate MOG-EM from MS.
K E Y W O R D S
cerebrospinal fluid, multiple sclerosis, myelin oligodendrocyte glycoprotein, neuromyelitis 
optica spectrum disorders
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1  | INTRODUC TION
The association of immunoglobulin G (IgG) autoantibodies directed 
against myelin oligodendrocyte glycoprotein (MOG) to different 
disease entities has been discussed1,2: MOG-IgG was initially de-
scribed in multiple sclerosis (MS), neuromyelitis optica spectrum 
disorders (NMOSD), relapsing inflammatory optic neuritis (RION), 
acute demyelinating encephalomyelitis (ADEM), or limbic encepha-
litis.3-9 Yet, disorders associated with MOG-IgG have recently been 
proposed to form their own disease entity, MOG encephalomyelitis 
(MOG-EM).2,10
Diagnostic criteria and a list of atypical conditions for MOG-EM 
(“red flags”) have been suggested.2 However, these criteria have not 
yet been validated, and MOG-EM is associated with considerable 
phenotypic variability among different age groups.7,9,11-16
Differentiation of MOG-EM from other inflammatory central 
nervous system (CNS) disorders, especially the most common one 
MS, is crucial as it harbors therapeutic implications. In contrast 
to MS, treatment (and even necessity of long-term treatment) of 
MOG-EM is thus far unclear as there are no established predic-
tive markers to differentiate monophasic vs relapsing disease. 
Historically, MOG-IgG has been described as a potential part of 
MS pathophysiology6 demonstrating histopathological similarities 
between MOG-EM and MS.17 Differentiation between the two 
diseases remains challenging in routine clinical practice due to 
overlapping features and test-inherent issues such as false-posi-
tive findings.2,18,19
We retrospectively applied the proposed diagnostic criteria to a 
monocentric cohort of patients with borderline and positive results 
for MOG-IgG as detected in clinical practice in order to critically 
evaluate the likelihood of MOG-EM vs MS.
2  | METHODS
2.1 | Study design
In this retrospective study, clinical records of patients of the Dept. 
of Neurology or Child Neurology were screened for the presence 
of test results of MOG-IgG obtained during routine clinical workup 
between January 2015 (start of assay availability) and August 2018 
(data cutoff date). Clinical and paraclinical data were included of vis-
its for a documentation period from January 2000 to August 2018, 
and the history of previous relapses before this documentation pe-
riod was included as reported by patients during the visits. All pa-
tients with at least one positive or borderline result were included 
in the analyses.
We assessed demographics (age at onset, sex, comorbidities), 
disease characteristics (type of first symptoms, diagnosis, immu-
notherapies, relapses, expanded disability status scale [EDSS]20), 
laboratory parameters (MOG-IgG [n = 37], aquaporin-4 [AQP4-]IgG 
[n = 37], ANA [n = 33], p-ANCA/c-ANCA [n = 33], rarely other anti-
bodies, Table 2), cerebrospinal fluid (CSF), and MRI results. Results 
of CSF oligoclonal band (OCB) analysis were obtained from routine 
diagnostics (n = 36, isoelectric focusing, silver staining).
2.2 | Autoantibody testing
The presence of MOG-IgG in the serum of all patients was as-
sessed using two different cell-based assays: (a) until 04/2017, a 
FACS assay was performed at the University Hospital Basel, Prof. 
Derfuss, Basel, Switzerland, abbreviated as FACS. These samples 
were sent overnight and further processed according to the pub-
lished protocol.5,21 (b) since 05/2017, a commercial indirect immu-
nofluorescence test using HEK 293 cells expressing either AQP-4 
or MOG (FA 1128-1005-1; Euroimmun AG, measured in-house 
[MPH] according to the manufacturer's instructions, abbreviated 
as EUROIMMUN). Results of the FACS assay were classified as 
positive, negative, or borderline. Results of the in-house assay 
EUROIMMUN were expressed as titers (<1:10 negative, 1:10 
borderline, >1:10 positive). In order to assess the qualitative ro-
bustness of the two different methods, only a small number of 
samples (n = 6) taken at the same date were tested in both as-
says, n = 3 negative in both assays, n = 2 positive in both assays 
(Table 2, pat. 16 and 27), and n = 1 borderline in FACS, negative in 
EUROIMMUN (Table 2, pat. 20).
All test results are summarized for all patients in Table 2. MOG-
IgG was available for each patient from 1 up to 4 times.
All other autoantibodies (ANA, p- and c-ANCA, and paraneoplas-
tic antibodies) were measured in the clinical routine laboratory.
2.3 | MRI
Cerebral and spinal MRI scans were performed with in-house stand-
ard protocols for demyelinating disorders: MR images were acquired 
on 3 Tesla (T) and 1.5T MR scanners (Magnetom Verio 3T; Magnetom 
Trio 3T; Magnetom Avanto 1.5T and Magnetom 1.5T Aera; Siemens 
Healthcare) with the standardized MS protocol. Generally, for fol-
low-up scans, the same scanner was used as in the first MRI scan. All 
images were routinely evaluated by trained neuroradiologists. For 
this analysis, all scans were manually re-evaluated by the investiga-
tors for the presence of MRI red flags as defined in Table 1.
2.4 | Application of diagnostic consensus criteria for 
MOG-EM and “red flags”
The recently published criteria and proposed “red flags”2 were evalu-
ated for the initial cohort of n = 40 patients. The red flags “bi-/trispe-
cific MRZ reaction,” “MOG-IgM/-IgA with negative MOG-IgG,” and 
“MOG-IgG in CSF, but not in serum” could not be evaluated as these 
are not part of the routine clinical workup in our center (Table 1).
For patients fulfilling the diagnostic criteria, we assessed the 
presence of red flags and thus defined three groups:
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• Definite MOG-EM (as proposed by2)
• Possible MOG-EM (as proposed by2)
• Unlikely MOG-EM: presence of the red flag “MOG-IgG at assay 
cutoff” plus a negative retest for MOG-IgG or at least one addi-
tional red flag.
2.5 | Analysis and statistics
Descriptive statistics were used to summarize patient data. For 
categorical variables, absolute and relative frequencies are re-
ported. For continuous variables, median and interquartile range 
(IQR), if deemed informative, also minimum (min.) and maximum 
(max.) are given. Frequencies of missing data are disclosed for each 
parameter. Group comparisons were performed with Kruskal-
Wallis test as a nonparametric test. Chi-square test was used to 
calculate difference in OCB and clinical diagnosis distribution be-
tween MOG-EM groups. Statistical significance level was set to 
P < .05.
All analyses were performed with GraphPad Prism version 7.03 
for Windows, GraphPad Software.
2.6 | Ethics approval
This study was approved by the responsible ethics committee (can-
tonal ethics committee Bern, registration no. KEK-BE 2017-01369). 
For this retrospective analysis, pseudonymized patient data were 
included. A separate informed consent was waived by the commit-
tee. For patients seen after the introduction of the general con-
sent (Feb-2015), the presence of the patients’ general consent was 
checked before inclusion in the analysis. Pediatric patients and their 
legal representatives were individually asked for their consent to the 
pseudonymized use of data by their treating physician (SB), as these 
are not covered by the general consent.
3  | RESULTS
3.1 | Characteristics of the cohort
We identified n = 40 patients with borderline or positive MOG-
IgG. Of this initial group, n = 3 patients did not demonstrate clinical 
findings compatible with a demyelinating event (functional disor-
der, episodic vertigo, depression, each n = 1). Two of these three 
had normal brain MRI scans and were tested positive in FACS with 
no retest available and a negative retest in EUROIMMUN, respec-
tively. For the third patient tested borderline in EUROIMMUN, 
neither a retest, nor further clinical or paraclinical data were avail-
able. These three presumably false-positive/borderline patients 
not fulfilling the diagnostic criteria were excluded from further 
analyses.
The remaining 37 patients fulfilling the diagnostic criteria were 
included in the analyses.
The female-to-male ratio was 1.6:1 (Figure 1). The median age 
at onset was 28.0 years (IQR 18.5-40.5, min. 9.0, max. 66.0). The 
last documented median EDSS was 2.0 (IQR 1.5-3.0, min. 0, max. 
8.0).
As part of routine clinical care, patients were given different di-
agnoses of demyelinating CNS disorders (Figure 2).
Classified by EDSS functional system scores, symptoms at onset 
were almost equally poly (n = 16)- or monosymptomatic (n = 18) with 
visual (n = 12), sensory (n = 13), and pyramidal (n = 9) being the most 
frequent (Figure 3A).
The syndrome at first manifestation was mainly spinal cord or 
optic nerve involvement (Figure 3B).
1 Chronic progressive disease course
2 Sudden onset of symptoms (<4 h)
3 Continuous worsening of symptoms over weeks
4 Lesion adjacent to a lateral ventricle that is ovoid/round or inferior temporal lobe lesion 
or Dawson's finger type lesions (ie, “lesions suggestive of MS”)
5 Active brain MRI with silent increase of lesion burden between relapses (limited 
evidence)
6 Bi-/trispecific MRZ reaction (not available for our data)
7 MOG-IgG at assay cutoff with/without atypical presentation
8 Positive MOG-IgM/-IgA with negative MOG-IgG (not available for our data)
9 MOG-IgG in CSF, but not in serum (not available for our data)
10 AQP4-IgG/ MOG-IgG double positivity (retesting recommended)
11 Findings suggesting diagnoses other than MOG-EM, MS or NMOSD
12 Combined central and peripheral demyelination
Abbreviations: AQP4, aquaporin-4; CSF, cerebrospinal fluid; h, hours; IgG/M/A, immunoglobulin 
G/M/A; MOG, myelin oligodendrocyte glycoprotein; MOG-EM, MOG encephalomyelitis; MRI, 
magnetic resonance imaging; MRZ, measles/rubella/zoster; MS, multiple sclerosis; NMOSD, 
neuromyelitis optica spectrum disorder.
TA B L E  1   Numbering of red flags, 
adapted from Jarius et al.2 Red flags 
are defined as conditions that should 
prompt physicians to challenge a positive 
test result and to consider retesting the 
patient, ideally using an alternative, that 
is, methodologically different, cell-based 
assay2
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3.2 | Evaluation of “red flags” and classification of 
likelihood of MOG-EM
A large proportion of patients (24/37) demonstrated at least one red 
flag (Table 2) and should thus be defined as “possible” MOG-EM.2 Most 
frequently, the MRI red flag “lesions suggestive of MS” was present 
(n = 18/37). In 16/37 patients, MOG-IgG was detected at the assay cut-
off. Progressive disease course was described in 5/37 patients. The MRI 
red flag “silent increase in lesion burden” was noted for 1/37 patient.
With the classification described above, that is, adding the cate-
gory “unlikely,” patients were categorized as “definite” (n = 13), “pos-
sible” (n = 11), and “unlikely” (n = 13) MOG-EM.
We classified one patient (pat. 26, Table 2) as “unlikely” with a 
single positive test result (FACS), but a negative pretest (FACS) and 
post-test (EUROIMMUN) for MOG-IgG and the additional red flag 
“lesions suggestive of MS.” This single patient is formally not consis-
tent with the definitions given above as the intermittent FACS result 
was indicated as positive, not borderline.
Among the “possible” group is one patient with confirmed border-
line results in the two different assays (FACS and EUROIMMUN) and 
the red flag “lesions suggestive of MS” (Table 2, pat. 6). Interestingly, 
this patient did not demonstrate CSF-specific OCB and experienced 
ongoing clinical and MRI disease activity while treated with glati-
ramer acetate, beta-interferon, dimethyl fumarate, and natalizumab, 
but is stable since introduction of B-cell depletion (15 months of fol-
low-up since initiation of rituximab).
Re-evaluating the cohort characteristics per diagnosis likelihood 
groups, the female-to-male ratio shifts for “definite” and “possible” 
MOG-EM close to 1:1 (Figure 1). Age at onset is not significantly dif-
ferent between groups (“definite”: median 22.0 years [IQR 16.0-32.5, 
min. 9.0, max. 52.0], “possible”: median 32.0 years [IQR 21.0-55.0, 
min. 19.0, max. 58.0], “unlikely”: median 28.0 years [IQR 17.5-37.5, 
min. 14.0, max. 66.0], P = .18), neither is the last documented EDSS 
(“definite” [n = 10]: median 1.5 [IQR 1.4-2.3], “possible” [n = 9]: me-
dian 2.5 [IQR 1.5-4.8], “unlikely” [n = 12]: median 2.3 [IQR 1.6-3.3], 
P = .38).
F I G U R E  1   Sex distribution of the 
cohort. Female (black bars) and male 
(white bars) patients according to the 
groups: whole cohort (“all,” n = 37), 
“definite” (n = 13), “possible” (n = 11), and 
“unlikely” (n = 13) MOG encephalomyelitis
F I G U R E  2   Diagnoses as given in clinical routine (before establishment of the term “MOG encephalomyelitis” (MOG-EM) and respective 
definition of diagnostic criteria). Black bars: whole cohort (n = 37), dark gray bars: “definite” MOG-EM (n = 13), light gray bars: “possible” 
MOG-EM (n = 11), white bars: “unlikely” MOG-EM (n = 13). For MS, the disease course is given, additionally. Autoimm., autoimmune; Bilat., 
bilateral; dis., disorder; inflamm., inflammatory; LETM, longitudinal extensive transverse myelitis; NMOSD, neuromyelitis optica spectrum 
disorder; ON, optic neuritis; PPMS, primary progressive MS; RION, relapsing inflammatory optic neuritis; RRMS, relapsing-remitting MS; 
SPMS, secondary progressive MS; unk., unknown
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Regarding clinical routine diagnoses, “unlikely” and “possible” 
MOG-EM mainly consisted of patients diagnosed with MS (11 of 13 
and 8 of 11, respectively, vs 5 of 13 in “definite” MOG-EM, P = .04, 
Figure 2).
For classification by EDSS functional system scores (Figure 3A) 
and by syndrome (Figure 3B) at onset, “definite” MOG-EM seems 
prone to involvement of the optic nerve (8 of 13) in our cohort. Due 
to the various groups of small size, no formal statistical analysis was 
run over this part.
3.3 | Pediatric-onset cases
All eight pediatric-onset patients demonstrated a spinal cord or 
optic nerve syndrome. The two youngest children in our cohort 
(11 and 9 years) experienced initial high-titer MOG-IgG (1:160 and 
1:320) that went back to borderline within 2 months and negative 
within 4 months, respectively, with thus far monophasic disease 
course (follow-up of 10 months after onset for both patients). 
Patients aged 17, 15, and 17 years (pat. 16, 23, and 28, Table 2) 
all experienced recurrent disease attacks (n = 2 RION, n = 1 with 
first attack of a bilateral ON, second/third attack: encephalitis and 
LETM in short sequence). These pediatric-onset patients were 
classified as “definite” MOG-EM (n = 5). The remaining n = 3 pa-
tients (aged 16, 17, 14 years) were classified as “unlikely” MOG-EM 
with the diagnosis of relapsing-remitting MS (RRMS, pat. 24, 26, 
35, Table 2). No ADEM manifestations were present in our inci-
dental cohort.
3.4 | Coexisting autoantibodies and autoimmunity
None of the tested sera showed positivity for coexisting AQP4-IgG 
(0/37). A positive ANA titer was detected in 5/33 patients (Table 2). 
F I G U R E  3   A, First symptom at disease onset, classified by EDSS functional system scores. If more than 1 symptom was reported, 
patients were counted as “polysymptomatic”, otherwise “monosymptomatic.” Black bars: whole cohort (n = 37), dark gray bars: “definite” 
MOG-EM (n = 13), light gray bars: “possible” MOG-EM (n = 11), white bars: “unlikely” MOG-EM (n = 13). For two patients, classification by 
functional system score was not deemed appropriate (multifocal, meningo-/encephalomyelitis); for three patients, symptoms at onset were 
unknown. Monosympt., monosymptomatic; polysympt., polysymptomatic; unk., unknown. B, Syndrome at first manifestation. Black bars: 
whole cohort (n = 37), dark gray bars: “definite” MOG-EM (n = 13), light gray bars: “possible” MOG-EM (n = 11), white bars: “unlikely” MOG-
EM (n = 13). For three patients, unknown syndrome at onset
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Patients with positive ANA were divided into “unlikely” (n = 2) and 
“possible” (n = 3) MOG-EM, respectively.
A patient with an atypical clinical manifestation (classified as 
autoimmune encephalomyelitis with reflex-myoclonus, classified 
“unlikely” MOG-EM) was extensively re-evaluated at the age of 
67 years. A MOG-IgG titer of 1:10 was detected, combined with a 
low-titer SOX-1 antibody. A large panel of other autoantibodies in 
this patient was negative, including GAD and IA-1 antibodies (co-
existing Diabetes mellitus). Due to repeated treatment with intra-
venous immunoglobulins after this first testing, retesting was not 
performed. This male patient experienced first symptoms at the age 
of 29 years. A neoplastic comorbidity was not found.
Secondary autoimmune diagnoses were found in three pa-
tients (autoimmune hepatitis, undifferentiated connective tissue 
disease, chronic juvenile arthritis, each n = 1, Table 2). These pa-
tients were divided into “unlikely” (n = 2) and “possible” (n = 1) 
MOG-EM.
3.5 | Para-/postinfectious disease onset
In our cohort, n = 4 patients demonstrated a para- or postin-
fectious disease onset (Table 2, “definite” [n = 3] and “possible” 
[n = 1] MOG-EM). In two patients (aged 21 years, female and 
24 years, male), no pathogen was detected in an extensive workup. 
Diagnoses were acute meningoencephalomyelitis, presenting with 
meningismus, phono-/photophobia, and fever (39°C) and longi-
tudinal extensive transverse myelitis (LETM), presenting 1 week 
after onset of pharyngitis/tonsillitis with persisting fever (38°C) 
at the day of admission under antibiotic treatment (cefuroxime), 
respectively.
In a female pediatric patient (aged 11 years) with LETM, a VZV 
primoinfection was detected, simultaneously.
A male patient (aged 45 years) experienced a severe EHEC sep-
sis with multiorgan failure. With a first manifestation of optic neu-
ritis (ON, right) 7 weeks later and sequential recurrent and bilateral 
ON, RION was diagnosed. MOG-IgG was first tested approximately 
12 weeks after EHEC sepsis (titer 1:10, during second attack) and 
meanwhile confirmed thrice with increasing titers (1:20; 1:40; 1:40). 
Serum available from the acute EHEC sepsis phase was retrospec-
tively tested and negative for MOG-IgG.
3.6 | Evaluation of CSF-specific oligoclonal bands in 
MOG-EM likelihood groups
Results of OCB testing were available for 36 patients (Table 2). 
Altogether, type 2 OCB (CSF-specific) were documented in 23 pa-
tients of the whole cohort, type 1 OCB (polyclonal) in 10 and type 4 
OCB (identical bands in CSF and serum) in 3 patients, respectively. 
As described before, only type 2 OCB (and type 3 which did not 
occur in our cohort) are CSF-specific, whereas type 1 and type 4 
OCB do not represent local IgG synthesis.2,22
The frequency distribution of the presence of CSF-specific 
OCB vs absence of CSF-specific OCB is significantly different be-
tween the groups “definite,” “possible,” and “unlikely” (P = .0005, 
Table 3).
4  | CONCLUSION
MOG encephalomyelitis has recently been proposed to form its own 
disease entity.1,2,10 However, both the clinical spectrum and differ-
ential diagnosis are thus far not well determined and proposed di-
agnostic criteria need broader validation which is challenging in a 
rare condition. In clinical practice, different methods of MOG-IgG 
testing harbor relevant differences in sensitivity and specificity.23 
Occurrence of low-titer MOG-IgG in patients with MS may cause 
clinically relevant delays in therapeutic decision making and ulti-
mately represent false-positive findings.18
We present a monocentric cohort of 37 well-characterized pa-
tients with suspected MOG-IgG-associated disorder and retrospec-
tively applied the proposed diagnostic criteria and red flags as well 
as OCB to differentiate MOG-EM from MS.
Regarding basic demographic and clinical results, our cohort is 
in line with existing data.14,15,24 The shift of the female-to-male ratio 
to 1:1 after exclusion of “unlikely” MOG-EM might rather be related 
to sample size.
We retrospectively applied the proposed diagnostic criteria and 
red flags2 to our cohort of suspected MOG-EM. A remarkable pro-
portion of patients had either MOG-IgG at the assay cutoff and/or 
MRI lesions suggestive of MS. This prompted us to define a group of 
“unlikely” MOG-EM in addition to the “possible” group as suggested 
in the consensus paper.2
With this classification, significantly more patients with a clinical 
diagnosis of MS prior to antibody testing were grouped as “unlikely” 
or “possible” than “definite”.
It is thus important to develop tools that help to better differ-
entiate MOG-EM from MS, in particular as this harbors therapeutic 
implications: MS can be treated with several immunotherapies, but 
MOG-EM may not only not respond, but even worsen under estab-
lished MS treatments.13,14
Borderline MOG-IgG titers with a negative retest or additional 
MRI red flags may thus lead us to reject the diagnosis of MOG-EM. 
TA B L E  3   Frequency distribution of presence vs absence of 
cerebrospinal fluid (CSF-)-specific oligoclonal bands (OCB) of the 
patients according to MOG encephalomyelitis (MOG-EM) groups 
“definite,” “possible,” and “unlikely” (P = .0005, chi-square test)
Definite 
MOG-EM
Possible 
MOG-EM
Unlikely 
MOG-EM
CSF-specific OCB 3 8 12
No CSF-specific 
OCB
10 2 1
Abbreviations: CSF, cerebrospinal fluid; MOG-EM, MOG 
encephalomyelitis; OCB, oligoclonal bands.
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However, given our small cohort, corroboration of our findings is 
necessary.
It has to be kept in mind that assay-related issues, that is, 
false-positive findings, may contribute to our findings primarily with 
regard to the commercially available EUROIMMUN assay—as puta-
tively in many other centers. Whereas the EUROIMMUN assay per-
forms less well than live cell-based assays in terms of the positive 
predictive value, it still generally provides good agreement with the 
latter with comparable specificity and negative predictive values.23 
As a limitation, we cannot directly compare EUROIMMUN results 
to the performance of the previous FACS assay as only very few 
samples of the same date were simultaneously analyzed in both as-
says. A direct comparison between the assays was thus not distinctly 
performed. For some of our patients, negative retests of borderline 
FACS results were detected with the EUROIMMUN assay. However, 
for several patients we cannot provide retest data (both for FACS 
and EUROIMMUN) and we do not have confirmatory results from a 
live cell-based assay. As a consequence, in clinical practice, retesting 
should be considered in borderline results and be performed, when-
ever possible, using both the routinely available assay and also an 
additional method, preferentially a live cell-based assay in a refer-
ence center.
Pediatric disease onset is mainly associated with optic nerve 
and spinal cord involvement as first symptom in our and in other 
cohorts.25,26 However, as this does not sufficiently distinguish 
MOG-EM from MS in children and adolescents, the differentia-
tion toward MS is crucial as we identified 3 patients as “unlikely” 
MOG-EM with our definition that were all diagnosed with RRMS and 
experienced sequential relapses. Corroborating previous findings, 
these 3 patients were older at onset (16, 17, and 14 years, respec-
tively) and demonstrated OCB type 2 (Table 2).27 This is therapeuti-
cally relevant as younger patients with “true” transient MOG-IgG are 
more likely to be monophasic as described in our cohort, whereas 
both RRMS and older adolescent patients with persisting MOG-IgG 
are at risk for sequential relapses with potential severe disability and 
thus require immunotherapy.1,27
Single cases of para-/postinfectious disease manifestations of 
MOG-EM were described before, both in adults and in children.14,28 
In all our patients, signs of systemic infection were still present at 
the onset of MOG-EM and/or a distinct pathogen was identified. 
Postinfectious disease onset is likely to be underdiagnosed, espe-
cially if MOG-EM occurs within weeks after a common trivial infec-
tion. With the negative MOG-IgG result of the patient during EHEC 
sepsis, disease manifestation of MOG-EM with RION phenotype 
7 weeks later and sequential confirmed positive MOG-IgG, our work 
may imply a possible underlying pathogenesis that involves trigger-
ing a general immune response29 or molecular mimicry processes.30
After classification of MOG-EM likelihood groups, patients with 
coexisting ANA autoantibodies or another autoimmune disease 
were not present in the “definite” MOG-EM group. As in other co-
horts, the small sample size limits wide interpretations. Yet, both 
ANA and coexistence of other autoimmune conditions have been 
described to be a potential help in differentiation vs AQP4-IgG pos-
itive NMOSD.31 As we did not compare to an NMOSD cohort, we 
cannot validate this finding with our data. Detectable (mainly low-ti-
ter) autoantibodies including ANA and MOG-IgG may occur within 
an autoimmune condition that does not qualify for MOG-EM and 
even in healthy persons; these may thus be unspecific or false-pos-
itive findings32,33 and argue for testing of MOG-IgG only in sus-
pected cases of a demyelinating CNS disorder.2
In addition to the application of the proposed red flags, we eval-
uated CSF-specific OCB. As addressed in the diagnostic criteria, the 
absence of CSF-specific OCB in patients with suspected MS should 
trigger MOG-IgG testing.2 In turn, their presence may also be used 
to challenge the diagnosis of MOG-EM, especially if they occur in 
combination with the named red flags. This is supported by our and 
other data.31
Due to the retrospective nature of our analysis without avail-
able retesting of MOG-IgG for all, particularly borderline-tested, pa-
tients, we cannot exclude that false-positive findings of MOG-IgG 
are present in the “possible,” and maybe even in the “definite” group. 
This situation will frequently occur in clinical practice. In addition, 
our study has the limitation of a small sample size. Nevertheless, for 
a rare and recently defined condition, our cohort, albeit small, con-
tributes to a better understanding of MOG-EM and differential di-
agnoses, especially MS, corroborating known data from other small 
cohorts and adding new insights. The inclusion of both the proposed 
combination of red flags and CSF findings to challenge or even rule 
out the diagnosis of MOG-EM in suspicious cases may be valuable 
if further confirmed in other cohorts in order to prevent treatment 
delays. Collaborative prospective studies are warranted to provide 
sufficient sample sizes and further elaboration of the differential di-
agnostic algorithm.
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